SAN DIEGO, April 20, 2026

QuidelOrtho Corporation has completed its acquisition of LEX Diagnostics for approximately $100 million, marking a significant expansion in its point-of-care molecular diagnostics portfolio. The deal strengthens the company’s position in rapid PCR testing technologies, highlighted by the integration of the LEX VELO System, an ultra-fast platform capable of delivering lab-quality diagnostic results in under 10 minutes.

Ultra-Fast PCR Platform Transforms Point-of-Care Testing

At the core of the acquisition is the LEX VELO System, a breakthrough molecular diagnostic platform that enables multiplex RT-PCR testing for Influenza A, Influenza B, and COVID-19 directly from patient swab samples. The system’s cartridge-based design eliminates the need for complex liquid handling, enabling rapid, accurate, and user-friendly testing in decentralized healthcare settings such as clinics, urgent care centers, and emergency departments.

The platform recently achieved U.S. FDA 510(k) clearance and CLIA waiver, confirming its clinical reliability and suitability for near-patient testing environments. With the ability to deliver results in approximately six to ten minutes, the system significantly enhances clinical decision-making speed, allowing healthcare providers to initiate timely treatment and improve patient outcomes.

This innovation addresses a growing demand for rapid diagnostics solutions, particularly in managing respiratory infections and infectious disease outbreaks, where speed and accuracy are critical.

Advertisement

cGxPJobs Banner

Strategic Expansion of Molecular Diagnostics Portfolio

The acquisition represents a key milestone in QuidelOrtho’s strategy to accelerate growth in the high-demand molecular diagnostics market, one of the fastest-growing segments in healthcare technology. By integrating LEX’s cutting-edge PCR platform, QuidelOrtho enhances its ability to deliver comprehensive diagnostic solutions across the continuum of care, from point-of-care settings to centralized laboratories.

The addition of the LEX VELO System complements QuidelOrtho’s established strengths in immunoassay, clinical chemistry, and transfusion medicine, reinforcing its leadership in integrated diagnostic technologies. The company plans to initiate the U.S. commercial launch later in 2026, followed by global expansion subject to regulatory approvals.

This move reflects a broader industry trend toward decentralized diagnostics, where portable, high-performance testing platforms are increasingly deployed closer to patients, reducing reliance on centralized laboratories and improving healthcare efficiency.

Advancing Faster, Smarter Healthcare Decisions

With the integration of LEX Diagnostics, QuidelOrtho aims to empower healthcare providers with real-time diagnostic insights, enabling faster clinical decisions and improved patient management. The ultra-fast PCR technology supports early detection and treatment, which is particularly critical in infectious diseases where rapid intervention can significantly reduce transmission and complications.

The acquisition also underscores QuidelOrtho’s commitment to innovation-driven growth, focusing on technologies that combine speed, sensitivity, and ease of use. By bringing advanced diagnostics closer to the patient, the company is helping to reshape the future of personalized and point-of-care medicine.

As highlighted in the press release, this strategic investment aligns with the company’s long-term vision to deliver connected diagnostic solutions that enhance healthcare outcomes and support global health systems.

The completion of QuidelOrtho’s acquisition of LEX Diagnostics marks a transformational step in rapid molecular diagnostics, introducing a powerful platform that delivers PCR-quality results in minutes. With the upcoming commercial launch of the LEX VELO System, the company is poised to drive innovation in point-of-care testing, improving diagnostic speed, accuracy, and accessibility worldwide.

Source: QuidelOrtho, LEX Diagnostics press release